Difference between revisions of "Lung cancer after neoadjuvant therapy"

From Libre Pathology
Jump to navigation Jump to search
(create)
 
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Creating Lung cancer after neoadjuvant therapy''' is assessed using a consensus protocol.<ref>{{cite journal |authors=Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y |title=IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy |journal=J Thorac Oncol |volume=15 |issue=5 |pages=709–740 |date=May 2020 |pmid=32004713 |pmc=8173999 |doi=10.1016/j.jtho.2020.01.005 |url=}}</ref>
'''Creating Lung cancer after neoadjuvant therapy''' is assessed using a consensus protocol.<ref>{{cite journal |authors=Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y |title=IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy |journal=J Thorac Oncol |volume=15 |issue=5 |pages=709–740 |date=May 2020 |pmid=32004713 |pmc=8173999 |doi=10.1016/j.jtho.2020.01.005 |url=}}</ref>
==Major pathologic response==
:<math>V ={ {T} \over {B} } \times 100 \%</math>
Where:
:V = percent viable tumour.
:T = tumour area.
:B = tumour bed area.
Major pathologic response is defined as: V <=10%.
==Sign out==
<pre>
At cut-up the tumour bed was estimated at 5.0 cm. The residual cancer's size is estimated as 1.5 cm (based on a linear measurement of the tumour on slide D15-D16). 
The estimated viable tumour was assessed in slides D14-D17 and was determined to be: 30%. The estimated viable tumour EXCEEDS the cut-off value (<=10%); thus, the specimen is NEGATIVE for a major pathologic response.[1] 
1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005
</pre>
===At cut-off value for major pathology response===
<pre>
The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for major pathologic response.[1]  Additional sections of the tumour bed are negative; thus, a major pathologic response is favoured.
1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005
</pre>


==See also==
==See also==
Line 7: Line 33:
{{Reflist|1}}
{{Reflist|1}}


[[Category:Lung pathology]]
[[Category:Pulmonary pathology]]

Latest revision as of 20:11, 21 February 2024

Creating Lung cancer after neoadjuvant therapy is assessed using a consensus protocol.[1]

Major pathologic response

Where:

V = percent viable tumour.
T = tumour area.
B = tumour bed area.


Major pathologic response is defined as: V <=10%.

Sign out

At cut-up the tumour bed was estimated at 5.0 cm. The residual cancer's size is estimated as 1.5 cm (based on a linear measurement of the tumour on slide D15-D16).  

The estimated viable tumour was assessed in slides D14-D17 and was determined to be: 30%. The estimated viable tumour EXCEEDS the cut-off value (<=10%); thus, the specimen is NEGATIVE for a major pathologic response.[1]  

1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005

At cut-off value for major pathology response

The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for major pathologic response.[1]  Additional sections of the tumour bed are negative; thus, a major pathologic response is favoured.

1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005

See also

References

  1. ↑ Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y (May 2020). "IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy". J Thorac Oncol 15 (5): 709–740. doi:10.1016/j.jtho.2020.01.005. PMC 8173999. PMID 32004713. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173999/.
Retrieved from "https://librepathology.org/w/index.php?title=Lung_cancer_after_neoadjuvant_therapy&oldid=52660"